{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3M-052-AF", "query": { "intervention": "3M-052-AF" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3M-052-AF&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T13:22:41.113Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04177355", "title": "Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "BG505 SOSIP.664 gp140", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "3M-052-AF", "type": "BIOLOGICAL" }, { "name": "CpG 1018", "type": "BIOLOGICAL" }, { "name": "GLA-LSQ", "type": "BIOLOGICAL" }, { "name": "Alum (Aluminum Hydroxide Suspension)", "type": "BIOLOGICAL" }, { "name": "Trimer 4571", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 127, "start_date": "2020-01-13", "completion_date": "2024-11-04", "has_results": true, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-09-02T13:22:41.113Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04177355" }, { "nct_id": "NCT04915768", "title": "Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CH505 TF chTrimer", "type": "BIOLOGICAL" }, { "name": "3M-05-AF", "type": "BIOLOGICAL" }, { "name": "Aluminum hydroxide suspension", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 51, "start_date": "2023-01-23", "completion_date": "2025-07-15", "has_results": true, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-09-02T13:22:41.113Z", "location_count": 3, "location_summary": "Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04915768" }, { "nct_id": "NCT06332339", "title": "Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "16055 NFL delta Gly4 trimer", "type": "BIOLOGICAL" }, { "name": "Trimer 4571", "type": "BIOLOGICAL" }, { "name": "Ad4-Env145NFL, 5 x 108 viral particles (vp)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 45, "start_date": "2024-03-15", "completion_date": "2026-11-11", "has_results": false, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-09-02T13:22:41.113Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06332339" }, { "nct_id": "NCT05471076", "title": "Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "426c.Mod.Core-C4b 30 mcg", "type": "BIOLOGICAL" }, { "name": "426c.Mod.Core-C4b 100 mcg", "type": "BIOLOGICAL" }, { "name": "426c.Mod.Core-C4b 300 mcg", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "BG505", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 52, "start_date": "2022-08-22", "completion_date": "2026-04-13", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-02T13:22:41.113Z", "location_count": 6, "location_summary": "Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05471076" }, { "nct_id": "NCT06006546", "title": "The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic HIV Infection" ], "interventions": [ { "name": "426c.Mod.Core-C4b", "type": "BIOLOGICAL" }, { "name": "Adjuvant 3M-052-AF+Alum", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 35, "start_date": "2024-01-03", "completion_date": "2026-10-27", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-09-02T13:22:41.113Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06006546" }, { "nct_id": "NCT06950177", "title": "Pancoronavirus Vaccine Study in Healthy Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19 Respiratory Infection", "SARS CoV 2 Infection", "COVID-19 Vaccine" ], "interventions": [ { "name": "CoV-RBD-scNP-001 and 3M-052-AF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 51, "start_date": "2025-07-08", "completion_date": "2026-08-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-02T13:22:41.113Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06950177" }, { "nct_id": "NCT06267872", "title": "A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "CD4BS CH505M5 Pr-NP1", "type": "BIOLOGICAL" }, { "name": "CH505TF chTrimer", "type": "BIOLOGICAL" }, { "name": "3M-052-AF (labeled as AP 60-702)", "type": "BIOLOGICAL" }, { "name": "Aluminum Hydroxide Suspension (Alum)", "type": "BIOLOGICAL" }, { "name": "ACU-026-001-1 (labeled as empty LNP)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2024-10-07", "completion_date": "2026-09-12", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-09-02T13:22:41.113Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06267872" }, { "nct_id": "NCT06334393", "title": "Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Zika", "Zika Virus Infection" ], "interventions": [ { "name": "VLA1601", "type": "BIOLOGICAL" }, { "name": "CpG 1018®", "type": "BIOLOGICAL" }, { "name": "3M-052-AF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Valneva Austria GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 150, "start_date": "2024-03-25", "completion_date": "2026-02-27", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-09-02T13:22:41.113Z", "location_count": 4, "location_summary": "Chicago, Illinois • Sioux City, Iowa • Lincoln, Nebraska + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Lincoln", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06334393" }, { "nct_id": "NCT05903339", "title": "Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hiv" ], "interventions": [ { "name": "V3G CH848 Pr-NP1 60mcg", "type": "DRUG" }, { "name": "3M-052-AF 5mcg", "type": "DRUG" }, { "name": "Alum 500 mcg", "type": "DRUG" }, { "name": "V3G CH848 mRNA-Tr2 50mcg", "type": "DRUG" }, { "name": "ACU-026-001-1 2.0mg", "type": "DRUG" }, { "name": "V3G CH848 Pr-NP1 100mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2023-08-29", "completion_date": "2026-12-18", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-02T13:22:41.113Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05903339" }, { "nct_id": "NCT05828095", "title": "A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "INO-6160, 2 mg", "type": "BIOLOGICAL" }, { "name": "Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2023-04-05", "completion_date": "2025-01-23", "has_results": true, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-09-02T13:22:41.113Z", "location_count": 3, "location_summary": "New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05828095" } ] }